Spring 2017

Health coverage and funding across seven industrial countries, with examination of variances and similarities in stated policy and outcomes by region and population mix. Recommended preparation: HCDA 501 and undergraduate degree in pharmacy, medicine, other healthcare, economics and administrative sciences or related disciplines; enrollment in a related MS or PhD program.

Basic introduction focused on the pathways and principles for managing new health technology discovery, funding, development, Food and Drug Administration (FDA) approval, and commerical market launch.

Quantitative methods of evaluating business, policy, pharmaceuticals, medical care resource allocations. Budget Impact Models, Decision Tress, Sensitivity Analysis tradeoffs between treatment strategies, interventions, risks, outcomes.

Comprehensive review of core biostatistics principles and applications through practical problem solving approach and case studies. Statistical methods, data validation and outcomes research, clinical trials.

Review and critique of health economics, P&T and outcomes literature. Core biostatical measures used to deconstruct and evaluate published research through case studies. Recommended preparation: HCDA 520.

Systematically review creativity and innovation techniques across healthcare industry, examine breakthrough genomic and biopharmaceutical processes and thinking, evaluate novel therapeutic and economic measures transforming outcomes.

Positioning products in global markets; market share targets, payer value, lifecycle and launch techniques, tools for formulary positioning and reimbursement

Weekly seminar and literature series, review and discuss policy, biopharmaceuticals, insurance, global healthcare access issues. Student lead discussions, expert guest speakers, group projects, critical thinking.

Research leading to the master's degree. Maximum units which may be applied to the degree to be determined by the department. Graded CR/NC.